Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Neil A. Pegg"'
Autor:
Luciano Nicosia, Gary J Spencer, Nigel Brooks, Fabio Amaral, Naseer Basma, John Chadwick, Bradley Revell, Bettina Wingelhofer, Alba Maiques-Diaz, Filippo Ciceri, Daniel H Wiseman, Neil A Pegg, William West, Tomasz Knurowski, Kris Frese, Karen Clegg, Victoria Louise Campbell, Mhairi Copland, Emma Searle, Tim C.P Somervaille
Publikováno v:
Blood. 140:8774-8775
Autor:
Luciano Nicosia, Nigel Brooks, Fabio Amaral, Oliver Sinclair, Neil A Pegg, William West, Tomasz Knurowski, Kris Frese, Karen Clegg, James Cavet, Emma Searle, Tim C.P Somervaille
Publikováno v:
Blood. 140:852-853
Autor:
Matthew J. Schiewer, Susana Miranda, William West, Suzanne Carreira, Stuart Thomson, Gareth W. Harbottle, Ana Ferreira, Stuart Thomas Onions, Donald Smyth, Nigel Brooks, Jonathan Shannon, Jonathan Welti, Nina Tunariu, Johann S. de Bono, Christopher McNair, Jenny Worthington, Wei Yuan, Karen E. Knudsen, Adam Sharp, Barbara Young, Amy Prosser, Jan Rekowski, Su C, Rita Pereira, Amanda Swain, Jian Ning, Abhijit Pal, Jordan Lane, Ruth Riisnaes, Bora Gurel, Ines Figueiredo, Mateus Crespo, Richard J. C. Brown, Saswati N. Chand, David Michel Adrien Taddei, Denisa Bogdan, Veronica Gil, Silvia Paoletta, Meera Raja, Neil Anthony Pegg, Antje Neeb
Publikováno v:
Cancer discovery. 11(5)
Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate AR
Autor:
Gary J. Spencer, Karen Clegg, Andrew Hughes, Tim C. P. Somervaille, John A. Chadwick, William H. West, Nigel Brooks, Tomasz Knurowski, Neil Anthony Pegg
Publikováno v:
Blood. 138:3291-3291
E1A binding protein (p300) and CREB binding protein (CBP) are two closely related histone acetyl transferases that co-activate key oncogenes such as MYC and IRF4 which are relevant in a number of haematological malignancies. Here we describe the effe
Autor:
Harriet S. Walter, Victoria Coyle, J.S. de Bono, A. Hughes, William H. West, T. Knurowski, Nigel Brooks, Fay Ashby, Simon Pacey, Neil Anthony Pegg, Louise Carter, Simon J. Crabb, Alastair Greystoke, Ruth Plummer, Karen Clegg
Publikováno v:
Annals of Oncology. 32:S617
Autor:
Harriet S. Walter, Tim C. P. Somervaille, Andrew Davies, William H. West, Nigel Brooks, Fay Ashby, Karen Clegg, Tomasz Knurowski, Neil Anthony Pegg, Steven Knapper
Publikováno v:
Blood. 134:1266-1266
Background CCS1477 is a first in class potent, selective and orally bioavailable inhibitor of the bromodomains of p300 and CBP, two closely related histone acetyl transferases with oncogenic roles in haematological malignancies. In pre-clinical studi
Autor:
Neil Anthony Pegg, Gary J. Spencer, Barbara W Young, Nigel Brooks, Meera Raja, Tim C. P. Somervaille
Publikováno v:
Blood. 134:2560-2560
E1A binding protein (p300) and CREB binding protein (CBP) are two closely related histone acetyl transferases with oncogenic roles in acute myeloid leukaemia (AML) and multiple myeloma (MM). Here we describe the pre-clinical characterization of CCS14
Publikováno v:
Cancer Research. 79:3826-3826
Background: CCS1477 is a potent and selective p300/CBP bromodomain inhibitor, currently in a Ph1 trial for patients with metastatic castration resistant prostate cancer (mCRPC). CCS1477 works by inhibiting the expression and function of the androgen
Autor:
Margaret M. Centenera, Lisa M. Butler, Natalie K. Ryan, Swati Irani, Anthony Nigel Brooks, Neil Anthony Pegg
Publikováno v:
Journal of Clinical Oncology. 37:e16534-e16534
e16534 Background: Growth and survival of prostate cancer cells are initially dependent upon androgens, and androgen deprivation therapy (ADT) is used to control tumor growth. Unfortunately, resistance to ADT inevitably occurs, and patients relapse w
Autor:
Elena Cojocaru, Johann S. de Bono, Karen Clegg, Tomasz Knurowski, William H. West, Fay Ashby, Anthony Nigel Brooks, Neil Anthony Pegg, Elizabeth Ruth Plummer
Publikováno v:
Journal of Clinical Oncology. 37:TPS5089-TPS5089
TPS5089 Background: CCS1477 is a potent, selective and orally bioavailable inhibitor of the bromodomain of p300 and CBP, two homologous and critical co-activators of the androgen receptor (AR) and its variant forms, including mutated, amplified and s